- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00941551
Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively
Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is commonly accepted that in patients with benign nodular thyroid disease who undergo operative therapy, surgical resection consists of lobectomy for patients with disease limited to one lobe. Contralateral disease is excluded in such cases by preoperative palpation, ultrasonography of the neck, and intraoperative palpation. On the other hand, the preferred operative procedure for bilateral nodular thyroid disease is total thyroidectomy. Such a treatment strategy minimizes the risk of development of recurrent disease and diminishes the risk of complications when reoperation for recurrent nodular thyroid disease becomes necessary. The recurrence rate for unilateral thyroidectomy of benign nodular goiter performed by expert surgeons has been reported to vary from 10% to 26%. Potential risk factors for recurrence of nodular goiter have been evaluated in many studies and include: young age at presentation, female gender, positive family history of goiter, long duration of symptoms, mutinodularity of thyroid disease, high volume of left thyroid tissue. However, most studies evaluating the incidence of recurrent nodular disease are retrospective, and it is difficult to determine whether the recurrence represents de novo nodule formation in a previously normal thyroid remnant or progression of residual disease left at initial operation.
It is well known fact, that most patients after thyroid lobectomy are euthyroid (60%-90%) and do not require thyroid hormone replacement therapy. However, it is an important question whether thyroid hormone administration postoperatively can prevent recurrent nodular thyroid disease in euthyroid hemithyroidectomized patients? The aim of the present randomized study was to compare the prevalence of recurrent nodular goiter in the contralateral thyroid lobe among patients after unilateral thyroid lobectomy for unilateral multinodular goiter (MNG) receiving versus not receiving prophylactic levothyroxine (LT4) treatment postoperatively in a five-year follow-up.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Krakow, Poland, 31-202
- Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- unilateral multinodular goiter with normal appearing on ultrasound of the neck contralateral thyroid lobe, in a patient in euthyroid state
Exclusion Criteria:
- bilateral multinodular goiter, enlargement of contralateral thyroid lobe (volume on ultrasound >10 ml), suspicion of thyroid cancer, previous thyroid surgery, thyroiditis, subclinical or clinically overt hypothyroidism or hyperthyroidism, pregnancy or lactation, age < 18 years or > 65 years, ASA 4 grade (American Society of Anesthesiology), and inability to comply with the follow-up protocol
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A
receiving levothyroxine postoperatively
|
levothyroxine 75-125 ug/day
Other Names:
|
Group B
not-receiving levothyroxine postoperatively
|
observation only without prophylactic levothyroxine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary outcome measure was prevalence of recurrent goiter within the contralateral thyroid lobe
Time Frame: at 3, 6, 9, 12, 24, 36, 48 and 60 months postoperatively
|
at 3, 6, 9, 12, 24, 36, 48 and 60 months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome was the rate of the reoperation for the recurrent goiter
Time Frame: at 3, 6, 9, 12, 24, 36, 48 and 60 months postoperatively
|
at 3, 6, 9, 12, 24, 36, 48 and 60 months postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marcin Barczynski, MD, PhD, Jagiellonian University College of Medicine
Publications and helpful links
General Publications
- Szybinski Z, Golkowski F, Buziak-Bereza M, Trofimiuk M, Przybylik-Mazurek E, Huszno B, Bandurska-Stankiewicz E, Bar-Andziak E, Dorant B, Kinalska I, Lewinski A, Klencki M, Rybakowa M, Sowinski J, Szewczyk L, Szponar L, Wasik R. Effectiveness of the iodine prophylaxis model adopted in Poland. J Endocrinol Invest. 2008 Apr;31(4):309-13. doi: 10.1007/BF03346363.
- Bellantone R, Lombardi CP, Boscherini M, Raffaelli M, Tondolo V, Alesina PF, Corsello SM, Fintini D, Bossola M. Predictive factors for recurrence after thyroid lobectomy for unilateral non-toxic goiter in an endemic area: results of a multivariate analysis. Surgery. 2004 Dec;136(6):1247-51. doi: 10.1016/j.surg.2004.06.054.
- Miccoli P, Antonelli A, Iacconi P, Alberti B, Gambuzza C, Baschieri L. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. Surgery. 1993 Dec;114(6):1097-101; discussion 1101-2.
- Bistrup C, Nielsen JD, Gregersen G, Franch P. Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up. Clin Endocrinol (Oxf). 1994 Mar;40(3):323-7. doi: 10.1111/j.1365-2265.1994.tb03926.x.
- Carella C, Mazziotti G, Rotondi M, Del Buono A, Zito G, Sorvillo F, Manganella G, Santini L, Amato G. Iodized salt improves the effectiveness of L-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study. Clin Endocrinol (Oxf). 2002 Oct;57(4):507-13. doi: 10.1046/j.1365-2265.2002.01628.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBN/501/ZKL/69/L
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Goiter
-
Steen BonnemaCompleted
-
Genzyme, a Sanofi CompanyCompletedMultinodular GoiterCanada, United States, France, Brazil, Italy, Denmark, Germany, Netherlands
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Hospital Universitari de BellvitgeUnknown
-
University Hospital, RouenCompletedGoiter, NodularFrance
-
Oklahoma State UniversityCompletedInfant Development | Iodine Deficiency GoiterEthiopia
-
Central South UniversityUnknown
-
National Taiwan University HospitalCompleted
Clinical Trials on levothyroxine
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulUnknownAging | Interaction Drug Food | Primary HypothyroidismBrazil
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | Subclinical Hypothyroidism | HypothyroxinemiaUnited States
-
Boston Children's HospitalCompleted
-
University of California, Los AngelesTerminatedHypothyroidismUnited States
-
Walter Reed National Military Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceWithdrawnSubclinical hypothyroïdismFrance
-
GlaxoSmithKlineCompletedHypothyroidismIndia
-
Assaf-Harofeh Medical CenterCompleted
-
Nova Scotia Health AuthorityNot yet recruitingSecondary Hypothyroidism
-
Ain Shams UniversityUnknown